Cumberland Pharmaceuticals reports top-line Ifetroban safety data in systemic sclerosis
Cumberland Pharmaceuticals announced top-line results from its ASSIST-SSC trial, showing Ifetroban was safe and well tolerated, according to Reuters.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to Reuters, Cumberland Pharmaceuticals has published top-line results from its ASSIST-SSC trial. Ifetroban showed safety and tolerability in patients with systemic sclerosis.
Most gastrointestinal adverse events were mild and resolved on their own. No serious adverse event linked to the drug was recorded over the 12-month treatment period, while mild bleeding-related events rose modestly.
why it matters
For investors, the news mainly concerns the company itself: it is an interim clinical data point for the drug rather than a financial result. Market reaction is likely to be limited, since the release does not assess efficacy.
tags
instruments
sources
- Cumberland Pharmaceuticals Announces Assist-Ssc Trial Top-Line Results — Reuters, 23 October 2026 at 22:14 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗